INM
Income statement / Annual
Last year (2024), InMed Pharmaceuticals Inc.'s total revenue was $6.29 M,
an increase of 14.77% from the previous year.
In 2024, InMed Pharmaceuticals Inc.'s net income was -$10.50 M.
See InMed Pharmaceuticals Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
Period Ended |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
Operating Revenue |
$6.29 M |
$5.48 M |
$1.40 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$4.78 M
|
$3.62 M
|
$702.87 K
|
$197.03 K
|
$183.09 K
|
$93.94 K
|
$92.78 K
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit |
$1.51 M
|
$1.86 M
|
$699.85 K
|
-$197.03 K
|
-$183.09 K
|
-$93.94 K
|
-$92.78 K
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit Ratio |
0.24
|
0.34
|
0.5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Research and Development Expenses |
$5.15 M
|
$4.94 M
|
$9.38 M
|
$5.34 M
|
$5.20 M
|
$4.30 M
|
$1.52 M
|
$573.72 K
|
$292.84 K
|
$759.85 K
|
General & Administrative Expenses |
$7.18 M
|
$7.75 M
|
$8.84 M
|
$4.48 M
|
$3.50 M
|
$6.00 M
|
$0.00
|
$2.79 M
|
$1.48 M
|
$2.62 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$7.18 M
|
$7.75 M
|
$8.84 M
|
$4.48 M
|
$3.50 M
|
$6.00 M
|
$5.17 M
|
$2.79 M
|
$1.48 M
|
$2.62 M
|
Other Expenses |
$300.33 K
|
$267.93 K
|
$239.05 K
|
$120.87 K
|
$161.97 K
|
$94.72 K
|
-$0.00
|
$75.22 K
|
$67.41 K
|
$75.76 K
|
Operating Expenses |
$12.63 M
|
$12.96 M
|
$18.46 M
|
$9.94 M
|
$8.87 M
|
$10.39 M
|
$6.69 M
|
$3.44 M
|
$1.84 M
|
$3.46 M
|
Cost And Expenses |
$17.41 M
|
$16.58 M
|
$19.16 M
|
$9.94 M
|
$8.87 M
|
$10.39 M
|
$6.78 M
|
$3.44 M
|
$1.84 M
|
$3.46 M
|
Interest Income |
$721.97 K
|
$652.37 K
|
$123.72 K
|
$16.02 K
|
$125.89 K
|
$330.44 K
|
$69.55 K
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$360.35 K
|
$18.62 K
|
$0.00
|
$0.00
|
$495.17
|
$47.92
|
$3.53 K
|
Depreciation & Amortization |
$826.76 K
|
$789.55 K
|
$658.96 K
|
$197.03 K
|
$183.09 K
|
$94.72 K
|
$89.60 K
|
$75.22 K
|
$67.41 K
|
$75.76 K
|
EBITDA |
-$10.30 M |
-$10.31 M |
-$17.10 M |
-$9.80 M |
-$8.58 M |
-$10.26 M |
-$6.69 M |
-$3.36 M |
-$1.77 M |
-$3.38 M |
EBITDA Ratio |
-1.64
|
-1.88
|
-12.19
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Operating Income Ratio |
-1.77
|
-2.03
|
-12.66
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Total Other Income/Expenses Net |
$637.29 K
|
$588.55 K
|
-$6.19 M
|
$2.12 M
|
$60.73 K
|
$262.10 K
|
$69.77 K
|
-$495.17
|
-$47.92
|
-$3.53 K
|
Income Before Tax |
-$10.49 M
|
-$10.51 M
|
-$23.95 M
|
-$10.20 M
|
-$8.68 M
|
-$10.10 M
|
-$6.71 M
|
-$3.44 M
|
-$1.84 M
|
-$3.46 M
|
Income Before Tax Ratio |
-1.67
|
-1.92
|
-17.07
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Income Tax Expense |
$9.71 K
|
$17.35 K
|
$0.00
|
$360.35 K
|
$18.62 K
|
-$262.10 K
|
$0.00
|
$495.17
|
$47.92
|
$3.53 K
|
Net Income |
-$10.50 M
|
-$10.53 M
|
-$23.95 M
|
-$10.20 M
|
-$8.94 M
|
-$10.01 M
|
-$6.71 M
|
-$3.44 M
|
-$1.84 M
|
-$3.46 M
|
Net Income Ratio |
-1.67
|
-1.92
|
-17.07
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
EPS |
-10.071 |
-43 |
-426.9 |
-470.6 |
-581.1 |
-640.1 |
-493.5 |
-412.6 |
-325.8 |
-768.3 |
EPS Diluted |
-10.071 |
-43.1 |
-427 |
-470.6 |
-581.1 |
-640.1 |
-493.5 |
-412.6 |
-325.8 |
-768.3 |
Weighted Average Shares Out |
$762.11 K
|
$244.54 K
|
$56.08 K
|
$26.88 K
|
$20.88 K
|
$20.71 K
|
$17.27 K
|
$10.84 K
|
$7.30 K
|
$5.59 K
|
Weighted Average Shares Out Diluted |
$762.11 K
|
$244.85 K
|
$56.08 K
|
$26.88 K
|
$20.88 K
|
$20.71 K
|
$17.27 K
|
$10.84 K
|
$7.30 K
|
$5.59 K
|
Link |
|
|
|
|
|
|
|
|
|
|